



A model for establishment, maintenance and reactivation of the immune response after vaccination against Ebola virus

Irene Balelli, Chloé Pasin, Mélanie Prague, Fabien Crauste, Thierry van Effelterre, Viki Bockstal, Laura Solforosi, Rodolphe Thiébaut

► To cite this version:

Irene Balelli, Chloé Pasin, Mélanie Prague, Fabien Crauste, Thierry van Effelterre, et al.. A model for establishment, maintenance and reactivation of the immune response after vaccination against Ebola virus. *Journal of Theoretical Biology*, 2020, 495, pp.110254. 10.1016/j.jtbi.2020.110254 . hal-03160892v2

HAL Id: hal-03160892

<https://hal.science/hal-03160892v2>

Submitted on 24 Jun 2020

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

A model for establishment, maintenance and reactivation of the immune response after vaccination against Ebola virus

Irene Balelli^{a,b,c,*}, Chloé Pasin^{a,b,c,d}, Mélanie Prague^{a,b,c}, Fabien Crauste^e,
Thierry Van Effelterre^f, Viki Bockstal^g, Laura Solfrosi^g, Rodolphe
Thiébaud^{a,b,c}

^a*INSERM U1219 Bordeaux Population Health, Université de Bordeaux, Bordeaux, France*

^b*INRIA SISTM team, Talence, France*

^c*Vaccine Research Institute, Créteil, France*

^d*Department of Pathology and Cell Biology, Columbia University Medical Center, New York, New York, USA*

^e*Université de Bordeaux, CNRS, Bordeaux INP, IMB, UMR 5251, F-33400 Talence, France*

^f*Janssen Pharmaceutica N.V., Beerse, Belgium*

^g*Janssen Vaccines & Prevention B.V., Leiden, The Netherlands*

Abstract

The 2014-2016 Ebola outbreak in West Africa has triggered accelerated development of several preventive vaccines against Ebola virus. Under the EBO-VAC1 consortium, three phase I studies were carried out to assess safety and immunogenicity of a two-dose heterologous vaccination regimen developed by Janssen Vaccines and Prevention in collaboration with Bavarian Nordic. To describe the immune responses induced by the two-dose heterologous vaccine regimen, we propose a mechanistic ODE based model, which takes into account the role of immunological memory. We perform identifiability and sensitivity analysis of the proposed model to establish which kind of biolog-

*Corresponding author

Email addresses: irene.balelli@u-bordeaux.fr (Irene Balelli),
cgp2121@cumc.columbia.edu (Chloé Pasin), melanie.prague@u-bordeaux.fr (Mélanie Prague), fabien.crauste@u-bordeaux.fr (Fabien Crauste), tvaneffe@ITS.JNJ.com (Thierry Van Effelterre), vbocksta@its.jnj.com (Viki Bockstal),
lsolforo@its.jnj.com (Laura Solfrosi), rodolphe.thiebaut@u-bordeaux.fr (Rodolphe Thiébaud)

ical data are ideally needed in order to accurately estimate parameters, and additionally, which of those are non-identifiable based on the available data. Antibody concentrations data from phase I studies have been used to calibrate the model and show its ability in reproducing the observed antibody dynamics. Together with other factors, the establishment of an effective and reactive immunological memory is of pivotal importance for several prophylactic vaccines. We show that introducing a memory compartment in our calibrated model allows to evaluate the magnitude of the immune response induced by a booster dose and its long-term persistence afterwards.

Keywords: Mechanistic modeling, Immunological memory, Vaccination, Ebola Virus, Identifiability analysis, Sensitivity analysis, Calibration, Heterologous vaccination

1. Introduction

Since the discovery of Ebola virus in 1976, recurring Ebola outbreaks have been recorded in equatorial Africa [1, 2]. The largest outbreak ever recorded has affected West Africa between March 2014 and June 2016 [3], during which a Public Health Emergency of International Concern was declared, and resulted in more than 28,000 cases and 11,000 deaths, since no licensed vaccines nor cure were available. On August 1st 2018 a new Ebola outbreak was declared in the Democratic Republic of Congo (DRC) in North Kivu and Ituri provinces [4]. At present, it has been confined to a relatively small area but has already caused more than 3400 confirmed cases and 2250 confirmed deaths updated to March 1st 2020 [5]: the World Health Organization (WHO) declared a Public Health Emergency of International Concern on July 17th 2019 [6].

Ebola virus (EBOV) belongs to the Filoviridae family, which includes five well-known species (Zaire (ZEBOV), Bundibugyo, Sudan, Reston and Tai Forest), and the recently discovered Bombali species [7]. Ebola virus causes Ebola Viral Disease (EVD), a severe and acute illness, with a mortality rate ranging from 25% to 90% according to the WHO [2]. Therefore, there is an urgent need for licensed Ebola vaccines.

In response to the 2014-2016 Ebola outbreak, the development of several vaccine candidates against Ebola virus has been accelerated, with various

vaccine platforms and antigen inserts [8, 9]. In this context, in December 2014 the EBOVAC1 consortium was built under the Innovative Medicines Initiative Ebola+ Program. Its purpose was to support the development by Janssen Vaccines & Prevention B.V. of a new two-dose heterologous vaccine regimen against Ebola based on Adenovirus serotype 26 (Ad26.ZEBOV) and Modified Vaccinia Ankara (MVA-BN-Filo) vectors [10]. Ad26.ZEBOV vector encodes the glycoprotein (GP) of the Ebola Zaire virus, while MVA-BN-Filo encodes GPs from Ebola Zaire virus, Ebola Sudan virus, Marburg virus, and Tai Forest virus nucleoprotein.

The proposed two-dose regimens utilize both vaccines, administered at 28 or 56 days intervals. Three phase I studies have been carried out in four countries under EBOVAC1: United Kingdom [11, 12], Kenya [13], Uganda and Tanzania [14]. The immune response following vaccination has been evaluated up to one year after the first dose through GP-specific binding antibody concentrations. Neutralizing antibody and T cell responses have also been evaluated up to one year of follow-up. Although human efficacy data are not available, results on non-human primate models have shown that the antibody concentration after the challenge correlates best with survival upon intramuscular challenge with Ebola virus [15, 16, 17, 18].

Therefore, it becomes relevant to estimate the persistence of the antibody response induced by the two-dose heterologous vaccine. The *in silico* approach we propose here will provide a good starting point to predict the humoral immune response elicited by the proposed vaccination regimen beyond the available persistence immunogenicity data.

The goal of prophylactic vaccination is to induce immunity against an infectious disease. Henceforth, it aims at stimulating the immune system and its ability to store and recall information about a specific pathogen, leading to a long-term protective immunity. This is possible by means of immunological memory, one of the core features of adaptive immune responses [19, 20, 21].

By generating specific antibodies, B cells play a key role in the mammalian adaptive immune system, and help protecting the organism against antigenic challenges. Several populations of specific B cells are generated upon antigen stimulation, with distinct functional roles. Naïve B cells become activated through the encounter with the antigen in secondary lym-

phoid organs. Upon activation, they can either become short-lived Antibody Secreting Cells (ASCs), or seed highly dynamic environments called Germinal Centers (GCs). In the second circumstance, B cells undergo B cell receptor (BCR) affinity maturation to improve their affinity against the presented antigen. The interaction of B cells with follicular dendritic cells and follicular helper T cells within GCs allows selection of B cells with improved antigen-binding ability [22]. During the course of a GC reaction, B cells can become either memory B cells or long-lived ASCs depending on the strength of their affinity. In particular, long-lived ASCs are generated after extensive B cells affinity maturation and produce high affinity antibodies. In contrast, memory B cells undergo less extensive affinity maturation, making them promptly available. Ultimately, ASCs are differentiated B cells able to produce high-affinity antibodies [22, 23, 24].

The primary infection induces a transient antibody response, because it is mostly characterized by short-lived ASCs. Indeed, findings on the kinetics of circulating ASCs following vaccination show an early peak located around 7 days after vaccination, followed by a rapid relaxation phase: their level becomes undetectable after 10 to 14 days [25, 26, 27]. Nevertheless, the primary infection is able to elicit memory B cells, which play a key role in protection against subsequent infections with the same pathogen. Indeed, secondary exposure to a priming antigen is characterized by a more rapid and intense humoral response, which is of better quality as well (*i.e.* higher affinity antibodies) [28, 29]: this is the so called anamnestic response. Memory B cells can directly differentiate into short-lived ASCs, as well as seed new GCs for further affinity maturation [22, 30]. This is done in a more effective way than naïve B cells: it has been experimentally observed that memory B cells possess an intrinsic advantage over naïve B cells in both the time to initiate a response and in the division-based rate of effector cell development [29]. Once the infection has been controlled, the generated population of specific B cells contracts, leaving memory B cells and long-lived ASCs. The latter population partially migrates to the bone-marrow and assures long-term production of high-affinity antibodies [31, 32].

Mathematical models of the immune response are increasingly recognized as powerful tools to gain understanding of complex systems. Several mathematical models have already been developed to describe antibody decay dynamics following vaccination or natural infection aiming at predicting long-

term immunity. The more popular models are simple exponential decay models (*e.g.* [33, 34]), bi-exponential decay models (*e.g.* [35, 36]) or power-law decay models (*e.g.* [37]). They are based on the assumption that antibody concentrations will decay over time. Changing slopes can be introduced to better fit immunological data, which typically show a higher antibody decay during the first period after immunization followed by a slower antibody decay.

ODE-systems are an extremely useful tool to model complex systems, because they are relatively easy to communicate, new biological assumptions can be included and several softwares exist to compute numerical solutions. To gain better insights on the dynamics of the humoral response, Le *et al.* [38] proposed a model taking into account a population of specific ASCs and applied it to fit data from both ASCs and antibodies upon vaccinia virus immunization of human volunteers. This is the extension of a model developed by De Boer *et al.* [39] and Antia *et al.* [40] for modeling the CD8 T cell response. As stressed by the authors, this model may underestimate long-term immunity since it does not take into consideration antibody contribution supplied by long-lived ASCs [31, 32].

The assumption of having several ASCs populations has been considered in several models thereafter. Fraser *et al.* [41] considered an extension of the conventional power-law decay model to include two distinct populations of ASCs, differing in their respective decay rate, showing an improvement of data fitting. Andraud *et al.* and White *et al.* [42, 43] developed models based on ordinary differential equations (ODEs) describing the contribution of short and long-lived ASCs in antibody production.

All previously cited models focus on the humoral response following immunization, without questioning the ability of the immune system to mount anamnestic responses. To the best of our knowledge, very few models have been proposed to address this question. An example is given by Wilson and Nokes [44, 45]. The authors explored different mechanisms for the generation of immune memory and its role in enhancing a secondary response upon further immunization against hepatitis B virus. The memory compartment included memory B and T cells and followed a logistic behavior. In this work, antibody and memory cell generation depended on the circulating antigen. The authors did not consider the contribution of any population of ASCs in

generating and sustaining the antibody response. A memory B cell compartment, where memory B cells are supposed to follow a logistic behavior and could differentiate into ASCs, has been considered by Davis *et al.* [46]. The authors parametrized a model based on 12 ODEs of the humoral immune response against Shigella, a diarrheal bacteria, to describe the complex interactions of the bacteria with the host immune system. Nevertheless, the complexity of the proposed model entails several identifiability issues, making it difficult to be used in practice.

Pasin *et al.* [47] have already analyzed the antibody response elicited by the two-dose heterologous vaccine regimens against Ebola virus based on Ad26.ZEBOV and MVA-BN-Filo, and evaluated during three phase I studies under the EBOVAC1 project. To this extent, they have used the model developed by Andraud *et al.* [42]. Model parameters have been estimated using a population approach and some key factors inducing variability in the humoral response have been identified and quantified. The model used by Pasin *et al.* focuses on the antibody response observed after the second dose, and can help predicting the durability of the antibody response following the two-dose heterologous regimens. However, the anamnestic response of any new exposure could not be studied, because no plasma cells nor memory B cells generation mechanism has been considered.

Here we want to extend the model developed by Andraud *et al.* [42] to characterize the establishment of the humoral response after the first vaccine dose and its reactivation following the second dose. The generation of different subgroups of B cells -memory, short- and long-lived ASCs- is taken into account and a vaccine antigen compartment is considered as responsible for inducing the immune response. We aim at understanding the ability of vaccinated people to react to a potential future encounter with Ebola virus antigens. To this extent, we develop a model able to describe the generation of an anamnestic response by means of the establishment of the immunological memory.

Description of studies performed under the EBOVAC1 project and a descriptive analysis of antibody concentrations are given in Section 2. In Section 3 we formulate our mathematical model describing the humoral response to a single immunization and explain how it can be used to simulate further immunizations. In Section 4 we perform structural identifiability analysis to

determine which data should be generated or alternatively which parameters should be fixed to allow proper parameter estimation. In Section 5 we perform a model calibration against available antibody concentration measurements. In Section 6, local sensitivity analysis completes previous results on parameter identifiability. With the parameter set obtained through calibration, in Section 7 we simulate a booster immunization which shows an improved immune response, due to the establishment of immunological memory elicited by the two-dose vaccination regimens. Finally in Section 8 we discuss the significance of obtained results and limitations of the model.

2. Study design and serological analyses

We consider data collected during three randomized, blinded, placebo-controlled phase I studies on healthy adult volunteers aged 18 to 50 years. Studies were performed in four different countries: UK, Kenya, Uganda and Tanzania. We present briefly these data here, because we will use them in next sections (*e.g.* Section 5). We refer to [11, 12, 13, 14] for a detailed presentation of safety and immunogenicity results, for studies in UK, Kenya and Uganda/Tanzania respectively.

In each country, participants were randomized into four vaccination groups differing by the order of vaccine immunizations (Ad26.ZEBOV as first dose and MVA-BN-Filo as second dose or conversely) and by the interval of time between immunizations (either 28 or 56 days). Throughout the paper we will label vaccination groups specifying the order of vaccine immunizations and delay between the first and second doses, *e.g.* participants within group Ad26/MVA D57 have received the first Ad26.ZEBOV dose at day 1 and the second MVA-BN-Filo dose 56 days later. Vaccination group Ad26/MVA D57 will be considered as the reference group. In each study 18 volunteers were enrolled per vaccination group, 3 receiving placebo and 15 receiving active vaccine.

We have analyzed data from a total of 177 participants subdivided as described in Table 1. For all groups immunogenicity measurements have been recorded at the first immunization day (day 1), 7 days later (day 8), at the second immunization day (day 29 or 57), at both 7 days (day 36 or 64) and 21 days (day 50 or 78) after the second immunization, and at days 180, 240

Table 1: Summary of data analyzed per vaccination group.

Group	No.	Measurements
MVA/Ad26 D29	44	D1, D8, D29, D36, D50, D180, D240, D360
MVA/Ad26 D57	44	D1, D8, D29, D57, D64, D78, D180, D240, D360
Ad26/MVA D29	45	D1, D8, D29, D36, D50, D180, D240, D360
Ad26/MVA D57	44	D1, D8, D29, D57, D64, D78, D180, D240, D360
Total	177	




Figure 1: Antibody concentrations dynamics per vaccination group in \log_{10} scale.

212 and 360 after the first immunization for the follow-up. Groups receiving the
 213 second dose at day 57 have an extra immunogenicity measurement at day 29.

214

215 The humoral immune response to the vaccine has been assessed through
 216 analysis of IgG binding antibody concentrations against the Ebola virus Kik-
 217 wit variant glycoprotein (EBOV GP). This was determined by enzyme-linked
 218 immunosorbent assay (ELISA) performed by Battelle Biomedical Research
 219 Center (BBRC, US) for the UK and Uganda/Tanzania studies and by Q2 So-
 220 lutions (US) for the Kenya study with assay-specific limit of detection (LOD)
 221 varying among analyzing laboratory (36.6 ELISA units/mL for (BBRC),
 222 26.22 ELISA units/mL for Q2 Solutions). Both laboratories used the same
 223 protocol and material for the assay.

224

225 In Figure 1 the dynamics of antibody concentrations (median and in-
 226 terquartile ranges) per vaccination group is given, considering data from the
 227 three studies pooled together (for further details, see supplementary Figure
 228 S1 and supplementary Table S1).

229

230 3. Mathematical model for primary and anamnestic response

231 3.1. Model formulation

232 To capture the establishment of the humoral immune response to a two-
 233 dose vaccination regimen and predict the reaction to a booster immunization
 234 we propose a mathematical model based on a system of five ODEs (Equations
 235 (1)-(5)). We consider three B cell populations: memory B cells (M), short-
 236 lived antibody secreting cells (S) and long-lived antibody secreting cells (L).
 237 In addition, we consider the concentration of antigen (A), which is introduced
 238 through immunizations, and causes primary as well as secondary responses.
 239 Finally, antibody concentration (Ab) is also described. For the sake of sim-
 240 plicity, we will denote this model as (MSL): a schematic representation is
 241 given in Figure 2. Equations of our model are:

$$(MSL) = \begin{cases} \dot{A} = -\delta_A A & (1) \\ \dot{M} = \tilde{\rho} A - (\tilde{\mu}_S + \tilde{\mu}_L) AM - \delta_M M & (2) \\ \dot{S} = \tilde{\mu}_S AM - \delta_S S & (3) \\ \dot{L} = \tilde{\mu}_L AM - \delta_L L & (4) \\ \dot{Ab} = \theta_S S + \theta_L L - \delta_{Ab} Ab & (5) \end{cases}$$




Figure 2: Schematic representation of (MSL) model. A stands for vaccine antigen, M for memory B cells, S for short-lived ASCs, L for long-lived ASCs, and Ab for specific soluble antibodies. See text and Equations (1)-(5) for details.

242 The reaction is initiated when a certain amount of antigen A is detected
 243 by the host immune defenses at time $t = 0$ (corresponding to the time of an
 244 immunization). The free antigen is progressively processed and eliminated

from the system with the per capita rate δ_A (Equation (1)). The antigen dynamic is described by a simple exponential decay, because in this particular context neither of the two vaccine vectors are replicating [11]. The presence of antigen causes the instantaneous generation of M cells at rate $\tilde{\rho}A$, condensing the complex biological process of activation of specific naïve B cells, and their subsequent massive proliferation and maturation within GCs. The M compartment is then an “hybrid” one. While the reaction is ongoing, M cells differentiate into both short- and long-lived ASCs, at rates $\tilde{\mu}_S$ and $\tilde{\mu}_L$ respectively. After total antigen consumption, M denotes memory B cells (BMEMs), ready to differentiate into ASCs upon subsequent antigen stimulation. ASCs are ultimately differentiated cells which do not proliferate. They die with rate δ_S and δ_L , respectively. Antibodies are produced by both populations of ASCs in different proportions ($\theta_S S + \theta_L L$). Their half-life is described by parameter δ_{Ab} . Description of all parameters can be found in Table 2.

After some time, the reaction reaches a peak, then the production of new ASCs and BMEMs decreases and finally ends. Long-lived ASCs continue to produce antibodies assuring long-term immunity, while BMEMs persist in the organism to promote anamnestic responses in case of subsequent encounters with the same antigen. Indeed, in this case, BMEMs can differentiate into antigen-specific ASCs and produce high-affinity antibodies.

3.2. Rescaled system

Compartment A is not observed in practice. In order to circumvent this difficulty, and to avoid identifiability issues (see Section 4), we can use the analytical solution of Equation (1) in Equations (2) to (5). We get:

$$\begin{cases} \dot{M} = \rho e^{-\delta_A t} - (\mu_S + \mu_L) e^{-\delta_A t} M - \delta_M M \\ \dot{S} = \mu_S e^{-\delta_A t} M - \delta_S S \\ \dot{L} = \mu_L e^{-\delta_A t} M - \delta_L L \\ \dot{Ab} = \theta_S S + \theta_L L - \delta_{Ab} Ab \end{cases} \quad (6)$$

Note that through this transformation the unknown parameters are $\rho := \tilde{\rho}A_0$, $\mu_S := \tilde{\mu}_S A_0$, $\mu_L := \tilde{\mu}_L A_0$ instead of $\tilde{\rho}$, $\tilde{\mu}_S$ and $\tilde{\mu}_L$, where $A_0 := A(t=0)$.

Table 2: Description of model parameters with units. We represent by $[A]$ the unit of antigen concentration: this quantity has not been measured in any study considered here.

Parameter	Description	Unit
δ_A	Antigen declining rate	days ⁻¹
$\tilde{\rho}$	Rate at which M cells are generated over time per antigen concentration	IgG-ASC.(10 ⁶ PBMC) ⁻¹ .days ⁻¹ . $[A]$ ⁻¹
$\tilde{\mu}_S$	Differentiation rate of M cells into S cells per antigen concentration	days ⁻¹ . $[A]$ ⁻¹
$\tilde{\mu}_L$	Differentiation rate of M cells into L cells per antigen concentration	days ⁻¹ . $[A]$ ⁻¹
δ_M	Declining rate of M cells	days ⁻¹
δ_S	Death rate of S cells	days ⁻¹
δ_L	Death rate of L cells	days ⁻¹
θ_S	Antibody production rate per S cells	ELISA Units.mL ⁻¹ .(IgG-ASC) ⁻¹ 10 ⁶ PBMC.days ⁻¹
θ_L	Antibody production rate per L cells	ELISA Units.mL ⁻¹ .(IgG-ASC) ⁻¹ 10 ⁶ PBMC.days ⁻¹
δ_{Ab}	Antibody death rate	days ⁻¹

274 3.3. Special case: no memory cells death

275 It has been reported in the literature that BMEMs are an exceptionally
276 stable population [48, 49]. It is hence reasonable to assume that $\delta_M \ll 1$.
277 Let us consider the rescaled system (6). Under the assumption $\delta_M = 0$, there
278 exists a stationary state reached by BMEMs, given by:

$$M \stackrel{\delta_M=0}{=} \frac{\rho}{\mu_S + \mu_L} \quad (7)$$

279 The state (7) is globally asymptotically stable [50]. The assumption
280 $\delta_M \ll 1$ will be useful to interpret results in Sections 5 and 7. However,
281 there is no constraint on this parameter in the sequel.

282
283 It is worth noting that in the case $\delta_M > 0$, the M population will con-
284 verge exponentially towards 0. Nevertheless, provided that $\delta_M \ll 1$ and in

particular $\delta_M \ll \delta_{Ab}$, the decreasing slope of M will be very small, hence the effect of δ_M will barely affect the Ab dynamics during the observation period.

3.4. Special case: absence of antigen stimulation

The model developed here extends a model proposed in [42] and applied in [47] in the context of the EBOVAC1 project to analyze the antibody response after the second dose. In these works the authors hypothesized that their observations began when the B cell response was already in the declining phase, *i.e.* there was no further generation of ASCs. In the absence of antigenic stimulus (*e.g.* $A_0 = 0$), (6) reduces to:

$$\begin{cases} \dot{M} = -\delta_M M & (8) \\ \dot{S} = -\delta_S S & (9) \\ \dot{L} = -\delta_L L & (10) \\ \dot{Ab} = \theta_S S + \theta_L L - \delta_{Ab} Ab & (11) \end{cases}$$

This corresponds to the model used in [42, 47], with the addition of Equation (8) which does not affect Equations (9)-(11).

3.5. Simulating the response to subsequent stimulations

The (MSL) model allows to describe the establishment of the humoral response by the first dose of antigen. To simulate the response to the second dose and subsequent stimulations, vaccine antigen is added to compartment A according to the vaccination schedule. Hence, the (MSL) model is applied again with predicted values of M , S , L and Ab the day of the planned second dose as new initial conditions. This can be mathematically formalized as follows.

Let n be the number of vaccine doses; t_i , $i = 1, \dots, n$ the time of administration of the i^{th} -dose and t_{n+1} the last observation time. Let $\psi_i := (\delta_{A,i}, \rho_i, \delta_{M,i}, \mu_{S,i}, \mu_{L,i}, \delta_{S,i}, \delta_{L,i}, \theta_{S,i}, \theta_{L,i}, \delta_{Ab,i})$ be the vector of unknown parameters associated with the immune response to the i^{th} -dose. We denote the initial conditions by M_0, S_0, L_0, Ab_0 .

For $t_i < t \leq t_{i+1}$, $i = 1, \dots, n$, the dynamics of M, S, L, Ab following the i^{th} -immunization is obtained as the solution to the following ODE system:

$$\begin{cases} \dot{M} = \rho_i e^{-\delta_{A,i}(t-t_i)} - (\mu_{S,i} + \mu_{L,i}) e^{-\delta_{A,i}(t-t_i)} M - \delta_{M,i} M \\ \dot{S} = \mu_{S,i} e^{-\delta_{A,i}(t-t_i)} M - \delta_{S,i} S \\ \dot{L} = \mu_{L,i} e^{-\delta_{A,i}(t-t_i)} M - \delta_{L,i} L \\ \dot{Ab} = \theta_{S,i} S + \theta_{L,i} L - \delta_{Ab,i} Ab \end{cases}, \quad (12)$$

314 with initial conditions: $M_0 = M(t = t_i), \dots, Ab_0 = Ab(t = t_i)$.

315 4. Identifiability analysis

316 We have performed a theoretical study of the rescaled model described
317 by (6) to determine which biological data are needed to accurately estimate
318 parameters and infer predictions about two-dose vaccination regimens.

319 *A priori* structural identifiability is a structural property of a model. It
320 ensures a sufficient condition for recovering uniquely unknown model param-
321 eters from knowledge of the input-output behavior of the system under ideal
322 conditions (*i.e.* noise-free observations and error-free model structure). We
323 refer to Miao *et al.* [51] for a formal definition of *a priori* structural identi-
324 fiability.
325

326
327 Ideally one would assess global structural identifiability, but sometimes
328 local identifiability can be sufficient if *a priori* knowledge on the unknown
329 parameters allows to reject alternative parameter sets. For instance, global
330 identifiability for (6) would not be reached without imposing any condition
331 on the half-life of compartment S compared to L . Indeed, from a structural
332 point of view, the roles of S and L are perfectly symmetric.

333
334 We assess local structural identifiability of (6) using the **Identifiabili-**
335 **tyAnalysis** package implemented in Mathematica (Appendix A). We sup-
336 pose that $Ab_0 = Ab(t = 0)$ is known and $Ab(t)$ is observed during follow-up,
337 which is consistent with available data (Section 2). If all other initial con-
338 ditions are unknown, (6) results in being non-identifiable (Supplementary
339 Table S2). The non-identifiable parameters are $L_0, M_0, S_0, \mu_L, \mu_S, \rho, \theta_L,$
340 θ_S , with degree of freedom 2. This means that, in order to solve the non-
341 identifiability issue, one should fix at least two parameters within the set of
342 non-identifiable parameters, $\{\mu_L, \mu_S, \rho, \theta_L, \theta_S\}$. However, there is no avail-
343 able information on the values of these parameters, hence they cannot be

fixed *a priori*. Therefore, additional biological data corresponding to other compartments need to be integrated to ensure structural identifiability.

Analyses of specific B cell response induced by vaccination could be performed through the Enzyme-Linked Immunosorbent Spot Assay (ELISpot). This is a sensitive method to identify the concentration of antigen-specific ASCs [52]. Antigen-specific BMEMs can also be analyzed through the ELISpot techniques, but this requires *ex vivo* polyclonal activation over 3 to 8 days before detectable amounts of antibodies can be found.

Specific ASCs correspond in (6) to $(S + L)(t)$. Let us assume they are measured during follow-up; baseline values of both S and L are still supposed unknown. We obtain that Model (6) with unknown parameter vector $\psi := (\delta_A, \rho, \mu_S, \mu_L, \delta_M, \delta_S, \delta_L, \theta_S, \theta_L, \delta_{Ab})$, and outputs vector $\mathbf{y}(t) = (Ab_0, Ab(t), (S + L)(t))$ is *a priori* structurally identifiable (Supplementary Table S2).

Let us assume that the M compartment is observed during follow-up instead of $S + L$. In this case, the structural identifiability of Model (6) is not ensured, according to the `IdentifiabilityAnalysis` algorithm (Supplementary Table S2). Other parameters should be fixed or information about ASCs should be integrated.

We can conclude that $\{Ab_0, Ab(t), (S + L)(t)\}$ is a suitable minimal output set to be considered to ensure model identifiability. Of course any other additional information about parameters and/or model compartments will increase the identifiability of (6) and the reliability of parameter estimation.

Of note, this analysis of theoretical identifiability still does not guarantee practical identifiability, which depends on availability and quality of data [51], such as time point distribution of measurements and measurements errors. However, practical identifiability could be improved by using a population approach for parameter estimation based on mixed-effects models [53, 54, 55]. This approach allows to perform parameter estimation across a whole population of individuals simultaneously, and quantify the variations that some covariates (either categorical and continuous) of interest produce over the dynamics of specific subgroups (*e.g.* heterogeneous vaccination schedules). This is done by assuming some underlying structure to the distribution of

individual-level parameters across a population. Firstly, each individual parameter is described by an intercept representing the mean parameter value across the whole population. Then, part of variability can be described by way of covariates allowing the distinction between different sub-populations, and finally a normally distributed random effect characterizes the remaining between-subjects unexplained variability. Within this framework, either maximum likelihood and Bayesian approaches has been proposed to perform parameter estimation.

5. Model calibration

Model (6) is not structurally identifiable with the observation of compartment Ab only: a reliable parameter estimation cannot be performed. Therefore, we propose a model calibration against antibody concentration data to assess the ability of (6) to reproduce antibody kinetics consistent with available experimental data.

5.1. Methods

To perform the calibration, we considered the antibody concentration data as described in Section 2.

We calibrated (6) considering the median and interquartile ranges among all studies pooled together stratified by vaccination group, considering vaccination group Ad26/MVA D57 as the reference group.

$M(0)$, $S(0)$, $L(0)$ and $Ab(0)$ were set equal to 0 before the first dose, *i.e.* we supposed there were no previously existing specific antibodies nor B cells. Initial conditions of the reaction to the second dose are set as the predicted values of each compartment at the second dose immunization day, as described in Section 3.5. Simulations of (6) have been performed using Matlab, `ode45` function. According to biological assumptions or previous modeling results, we suppose that the following parameters could be modified depending on the vaccine vector and/or the timing of dose administration (see Table 3 for notation details):

- ρ, μ_S, μ_L are vector dependent (Ad26.ZEBOV or MVA-BN-Filo). These parameters determine the strength of the humoral response and the

amount of ASCs and BMEMs generated (Section 3). Biological evidences suggest that the strength and quality of the immune response is dependent on the type of antigen inducing the reaction and the way it is presented (*e.g.* [56]).

- $\delta_S(\text{PVD1}) \geq \delta_S(\text{PVD29}) \geq \delta_S(\text{PVD57})$: Pasin *et al.* [47] have identified a significant effect of the delay between immunizations on δ_S by analyzing the same phase I data we are considering here, with a simplified mechanistic model.
- $\delta_S(\text{Ad26}) \neq \delta_S(\text{MVA})$: the effect of the order of administration of vaccine vector over the decay rate of short-lived ASCs has been evidenced in a previous analysis by Pasin *et al.* [47]. The higher complexity of the model described here allows to define a direct dependence between parameters and vaccine vectors: we allow parameter δ_S to change according to the vaccine vector used.
- $\rho(\text{PVD1}) < \rho(\text{PVD29}) \leq \rho(\text{PVD57})$: the secondary response is improved in magnitude with respect to the primary one, due to the presence of specific BMEMs contributing to the initiation of GCs reaction in a more effective way [29]. Parameter ρ determines the strength of the humoral response because it defines the generation of M cells upon antigen stimulation, *i.e.* the GC reaction breadth. Therefore M cells do not play exactly the same role when a primary (GCs generated from activated naïve B cells) or a secondary (GCs seeded by BMEMs or newly activated naïve B cells; BMEMs differentiating into ASCs) response is simulated [22, 28], hence it is reasonable to allow parameter ρ to increase from the first immunization ($\rho(\text{PVD1})$) to the following one ($\rho(\text{PVD29})$ or $\rho(\text{PVD57})$). In addition, previous studies on different viruses and vaccines have shown that an increased interval between immunizations is associated with an improved magnitude of the response (*e.g.* [57, 58]). Consequently, an additional variation of parameter ρ depending on the interval between the two doses is permitted.
- $\delta_A(\text{Ad26}) \leq \delta_A(\text{MVA})$: according to biodistribution and persistence results, Ad26 is cleared in approximately 3 months [59], while MVA is cleared in approximately 1 month [60]. Note that here antigen concentration defines the duration of the GC response, so it does not exactly reflect biodistribution.

Table 3: Let ψ be a generic (unknown) parameter in $\{\delta_A, \rho, \mu_S, \mu_L, \delta_M, \delta_S, \delta_L, \theta_S, \theta_L, \delta_{Ab}\}$. If it is dependent on the interval between immunizations or vaccine vector we write $\psi(\text{cat})$, “cat” being a possible category of each variability factor.

$\psi(\text{cat})$		
Factor	Category	Meaning
Timing	PVD1	Post vaccination at day 1
	PVD29	Post second vaccination at day 29
	PVD57	Post second vaccination at day 57
Vaccine vector	MVA	The vaccine vector is MVA-BN-Filo
	Ad26	The vaccine vector is Ad26.ZEBOV

Model calibration has been achieved by repeated simulations of (6) and parameter tuning, until we obtained a consistent parameter set able to reproduce reasonable antibody dynamics in accordance with interquartile ranges of experimental data for all vaccination groups.

5.2. Results

Table 4 shows parameter values obtained at the end of the calibration process described in Section 5.1.

In Figure 3, antibodies (Figure 3 (a)) and ASCs and BMEMs (Figure 3 (b)) dynamics are plotted for the reference vaccination group, Ad26/MVA D57, as an example. Results for all other vaccination groups are given in supplementary Figures S2-S3. The time axis is rescaled at the day of the primary injection (*i.e.* study day 1) and simulations performed up to 1 year after the first dose.

In Figure 3 (a), orange dots correspond to median values of antibody concentrations data from the corresponding vaccination group. We were able to satisfactorily reproduce antibody concentrations dynamics in accordance with experimental observations for all vaccination groups. In supplementary Table S3 further details are given, with comparison of simulations to real data at some point of interest, *e.g.* at the time of the observed antibody peak and one year after the first dose.

Table 4: Parameters set obtained through (MSL) model calibration and used for simulations plotted in Figure 3 and supplementary Figures S2-S3. The half-life corresponding to rate loss parameters is given by: $t_{1/2}(\delta_i) := \ln(2)/\delta_i$. Structurally identifiability of parameters with antibody concentrations observations is recalled, according to results of Section 4 (Y=structurally identifiable; N=structurally non-identifiable)

Parameter	Prior	Ref.	Value		Unit	Structurally identifiable with measured <i>Ab</i> only?
			Ad26	MVA		
$t_{1/2}(\delta_A)$	-	-	10.7	3.3	days (half-life is derived from the approximate time to clear Ad26.ZEBOV and MVA-BN-Filo respectively : $t_{1/2}(\delta_A)(\text{Ad26}) > t_{1/2}(\delta_A)(\text{MVA})$ [59, 60])	Y
ρ	-	PVD1	3.5	0.7	IgG-ASC/ 10^6 PBMC.days $^{-1}$	N
		PVD29	15	17		
		PVD57	15	20		
μ_S	-		2.5	0.4	days $^{-1}$	N
μ_L	-		0.011	0.0035	days $^{-1}$	N
$t_{1/2}(\delta_M)$	≥ 50	[49]	63.3		years	Y
$t_{1/2}(\delta_S)$	[0.8;7.7]	PVD1	0.7	0.7	days	Y
		PVD29	2.8	4.6		
		PVD57	4.6	11.6		
$t_{1/2}(\delta_L)$	[2.7;13]	[47]	9.5		years	Y
θ_S	-		20		ELISA Units/mL.(IgG-ASC/ 10^6 PBMC) $^{-1}$.days $^{-1}$	N
θ_L	-		30		ELISA Units/mL.(IgG-ASC/ 10^6 PBMC) $^{-1}$.days $^{-1}$	N
$t_{1/2}(\delta_{Ab})$	[22;26]	[47]	23.9		days	Y

474 The model predicts that antibody levels at one year after the first dose
 475 are comparable among all vaccine regimens, in accordance with data. The
 476 antibody response peak has been measured 21 days after the second dose.
 477 Antibody dynamics obtained with our calibration show a slightly delayed
 478 peak between 3 and 4 weeks after the second dose. Of note, no immuno-
 479 genicity measurements have been performed *e.g.* at 2 weeks nor at 4 weeks.

480
 481 In Figure 3 (b) the dynamics of B cells are plotted: for ASCs, we consider
 482 the sum of short- and long-lived ASCs. Note that, because the half-life of
 483 short-lived B cells is supposed to be significantly shorter than long-lived B
 484 cells one, at 1 year of follow-up we do not have any contribution from the S
 485 compartment.

486
 487 Results about B cell subsets dynamics correspond only to model predic-
 488 tions since they were not calibrated on real data, therefore model parameters
 489 could not be accurately determined. However, with the data available so far
 490 from phase I studies, this model provides a good starting point and it will
 491 be further implemented and validated when additional biological data on B-
 492 cells populations from ongoing phase II and phase III clinical studies will be
 493 available. ASCs dynamic shows an early peak located a few days (between 7
 494 to 10) after the second dose. This is in accordance with other studies assess-
 495 ing B cell kinetics upon vaccination (*e.g.* [26, 27]). It is followed by a rapid
 496 relaxation phase, then stabilization.

497
 498 The rapid decreasing slope after the peak of the ASCs response (*i.e.*
 499 from approximatively 1 to 10 weeks after the second dose) depends on the
 500 value of parameter δ_S , which corresponds to a very small half-life of short-
 501 lived ASCs (varying from almost 3 to 12 days, depending on the regimen).
 502 The concentration of long-lived ASCs is low for the obtained parameter set,
 503 but able to sustain the antibody response due to the long half-life of this
 504 population. BMEM level depends on parameters ρ , μ_S and μ_L , as stressed
 505 in Section 3.3 (note that according to Table 4 the half-life of M cells is set
 506 here at about 63 years, which implies a really weak value for parameter δ_M ,
 507 of the order of 10^{-5}).




Figure 3: Predictions from the calibrated (MSL) model for the reference group, Ad26/MVA D57. **(a)** Antibody concentrations (\log_{10} -transformed). Green horizontal lines denote detection levels used by the BBRC laboratory (solid line) and by the Q2 Solutions laboratory (dashed line) respectively. **(b)** B cells. S and L stand for short-lived and long-lived ASCs respectively; M represents BMEMs.

508 6. Sensitivity analysis of the antibody compartment

509 We have obtained a parameter set able to reproduce antibody responses
 510 dynamics to two-dose vaccine regimens against Ebola virus that closely re-
 511 semble experimental observations. We perform a local sensitivity analysis
 512 of the antibody compartment to clarify the effect of each parameter on it
 513 over time. This can help detecting two different sources of practical non-
 514 identifiability of parameters:

- 515 1. a very weak effect of a given parameter on the observed compartment
 516 or an effect which is concentrated in a specific time window where
 517 observations are very scarce;
- 518 2. the interplay among parameters: the effect of the variation of one pa-
 519 rameter on the observed compartment can be compensated by a suit-
 520 able variation of another parameter.

521 An intuitive representation of local sensitivity of the Ab compartment
 522 with respect to each parameter is given by the evaluation of curves $\phi_{\psi_i}(t) :=$

$$523 \frac{\psi_i}{Ab(t, \psi)} \frac{\partial Ab(t, \psi)}{\partial \psi_i} \bigg|_{\psi = \psi^*}, \text{ for each parameter } \psi_i \text{ in } \psi = \{\delta_A, \rho, \delta_M, \mu_S, \mu_L, \delta_S, \delta_L, \theta_S, \theta_L, \delta_{Ab}\}$$

524 [61]. The quotient ψ_i/Ab is introduced to normalize the coefficient and avoid
 525 influence of units.

526

527 6.1. Results

528 Partial derivatives of (6) Ab output with respect to each parameter are
 529 numerically evaluated (Appendix B). ψ^* is set at parameter values corre-
 530 sponding to the reference regimen, Ad26/MVA D57 (Table 4). In Figure 4,
 531 $\phi_{\psi_i}(t)$ for all ψ_i in ψ are plotted. The time axis is rescaled at the day of the
 532 second dose administration.




Figure 4: Relative sensitivity of the Ab compartment with respect to (MSL) parameters over time. For each parameter ψ_i in $\psi = \{\rho, \theta_S, \delta_S, \delta_A, \delta_{Ab}, \theta_L, \mu_S, \mu_L, \delta_M, \delta_L\}$ the normalized sensitivity coefficients are plotted: $\phi_{\psi_i}(t) := \frac{\psi_i}{Ab(t, \psi)} \frac{\partial Ab(t, \psi)}{\partial \psi_i} \Big|_{\psi=\psi^*}$. For the sake of clarity we shade differently time windows corresponding to distinct phases of the antibody kinetics: in green the first exponential phase, in yellow the antibody peak, in pink the declining phase, in blue the stabilization phase.

533

534 The influence of almost all parameters over Ab dynamics significantly
 535 changes over time. In particular, in the very early exponential phase after

536 vaccine immunization, parameters that mostly influence the antibody re-
537 sponse in (6) are ρ , which determines the intensity of the immune response
538 upon antigen stimulation, and θ_S and δ_S , characterizing the antibody pro-
539 duction rate of short-lived ASCs and their half-life respectively. Right after
540 the antibody peak, the most relevant parameters are the decay rate of antigen
541 δ_A and the half-life of antibodies δ_{Ab} . Asymptotically, we will mostly retain
542 the influence of δ_{Ab} and the antibody production rate of long-lived ASCs θ_L
543 (even if δ_A , ρ , and the differentiation rates of M cells into both compartments
544 of ASCs, μ_S and μ_L , also have a great influence).

545
546 From curves plotted in Figure 4 it is also possible to deduce in which
547 direction each parameter affects the Ab dynamics: increasing the values of
548 ρ , μ_L , θ_S and θ_L implies an increase in Ab concentration. The loss rates
549 δ_A , δ_S , δ_{Ab} , δ_L and parameter μ_S (starting from a few weeks post vaccination)
550 acts in the opposite way: an increase of their values is associated to a de-
551 crease of the Ab concentration. Note that the sensitivity of Ab with respect
552 to μ_S is positive during the first weeks after vaccination, because this param-
553 eter determines the generation of short-lived ASCs, which govern the early
554 antibody response.

555
556 The half-lives of both M and L populations are supposed to be signifi-
557 cantly greater than antibody half-life. This explains why parameters δ_M and
558 δ_L have an extremely low influence over Ab dynamics on the one-year period
559 considered and locally around parameter set given in Table 4. The reliability
560 of their estimations could be refined either by considering longer follow-up
561 or by integrating data related to these compartments (*cf.* specific BMEMs
562 and ASCs through the ELISpot technique).

563
564 Finally, Figure 4 shows that in absolute value, the sensitivity of Ab with
565 respect to some parameters seems to asymptotically stabilize at the same
566 value (starting from approximately 250 days after the second dose). We are
567 referring to *e.g.* (ρ, μ_L) in the same way, and (δ_{Ab}, θ_L) in opposite ways. This
568 has consequences on the identifiability of these parameters: the effect of the
569 variation of one among them can be compensated by a suitable variation of
570 its pair, at least over some specific time windows. This implies that if an-
571 tibody observations are collected exclusively within these time windows, it
572 would not be possible to accurately estimate these parameters individually,
573 due to their interplay.




Figure 5: Effects of a variation of both μ_S and μ_L of 50% on (a) Ab and (b) M (all other parameters are fixed as in Table 4).

A particular focus should be made on parameters μ_S and μ_L : the sensitivity of Ab with respect to these parameters is symmetric (in opposite way) over time starting early (few weeks) after immunization. Henceforth the Ab dynamics will be unchanged by preserving the quotient between μ_S and μ_L (note that (6) is not identifiable if the only observed compartment is Ab). In Figure 5 (a) we plot the Ab dynamics obtained when both μ_S and μ_L are increased by 50% simultaneously: we can see that the obtained curves are superposed. Nevertheless, the corresponding M dynamics is significantly affected by changes in the individual values of μ_S and μ_L , as shown in Figure 5 (b). This further stress the importance of integrating further biological data to proceed to parameter estimation in a reliable manner.

6.2. Conclusions

Sensitivity analysis is used to gain a better understanding of the practical identifiability of model parameters from antibody concentrations data.

The sensitivity of antibody dynamics with respect to parameters δ_M and δ_L is extremely weak: changing their values does not affect significantly the Ab output, at least in the considered time window. We conclude that these

parameters are practically non-identifiable considering only antibody data and one year of follow-up.

Parameters μ_S and μ_L are closely related, affecting antibody dynamics in a symmetric way. Antibody concentration data would not allow their estimation individually, due to their collinearity.

Other parameters will be practically non-identifiable due to data quality (*e.g.* time point distribution and/or measurements errors and limitations). In particular, one should pay particular attention to parameters which exclusively describe the reaction to the first vaccine dose. Indeed, very few antibody measurements are above the detection level before the second dose, in particular for patients primed with MVA-BN-Filo (Section 2).

7. Simulations of a booster dose

One of the main interests in modeling the establishment and reactivation of the immune response after multiple antigen exposures is the prediction of the effects of a booster dose. With (6) we can expect to be able to predict the strength of an anamnestic response by the mean of the establishment of an effective immunological memory.

We use the calibrated model (6) to simulate the response to an Ad26.ZEBOV booster dose, realized at day 360 after the first dose for vaccination group Ad26/MVA D57.

In order to simulate the first two immunizations (*i.e.* the regular two-dose schedule), we use the parameter set obtained in Section 5 (Table 4). The Ad26.ZEBOV booster dose is simulated using the parameter set corresponding to an Ad26.ZEBOV immunization 56 days after the first dose.

In Figure 6 we plot the dynamics of both antibodies (\log_{10} -transformed) and B cells (ASCs and BMEMs) as predicted by (6) for the second dose and booster immunizations. The time axis is rescaled to have time 0 corresponding to the second immunization day (*i.e.* day 57). Further information is given in supplementary Table S4.






Figure 6: Simulation of (MSL) for vaccination group Ad26/MVA D57 with a booster dose of Ad26.ZEBOV one year after the first dose (day 360). In (a) the obtained \log_{10} -transformed antibody concentration is given. In (b) S and L stand for short-lived and long-lived ASCs respectively; M represents memory cells. The time axis is rescaled at the second dose day (*i.e.* day 57).

629 Simulations show a strong humoral anamnestic response to the booster
630 immunization, with approximately a 11-fold increase of antibody concentra-
631 tion within 7 days post booster dose, and a 25-fold increase within 21 days
632 (in linear scale). This is due to the presence of a high affinity pool of BMEMs
633 which differentiate into ASCs directly upon antigen stimulation. In addition,
634 the model predicts a 2.5-fold increase in antibody concentration 360 days af-
635 ter the booster dose (*i.e.* day 720) compared to day 360.


636
637 In Figure 6 (b) we have plotted the corresponding B cell dynamics.
638 Again, we observe that ASCs increase drastically after the booster immuniza-
639 tion, hence stabilizes at a higher level than before, correlating with antibody
640 concentrations. After the booster dose, BMEMs stabilize at a lower level:
641 this depends on the calibrated values for parameters ρ , μ_S and μ_L under the
642 assumption that the effect of Ad26.ZEBOV as booster dose would be similar
643 to Ad26.ZEBOV at Day 57 as second dose. We anticipate that, from an im-
644 munological perspective, depletion of BMEM (Figure 6 (b)) is not reflecting
645 the immunological situation post booster dose, because replenishment of the
646 BMEM compartment is to be expected after booster vaccination. Otherwise,



(a) $M(t)$



(b) $Ab(t)$



(c) $(S + L)(t)$

Figure 7: Simulation of (MSL) for vaccination group Ad26/MVA D57 with a booster dose of Ad26.ZEBOV one year after the first dose (day 360), when both $\mu_S(\text{Ad26})$ and $\mu_L(\text{Ad26})$ for the booster dose of Ad26.ZEBOV are varied by (from top to bottom, see legend in (a)) 90%, 86%, 85%, 80%, 70%, 50%, 30% from the reference value as in Table 4 (purple curve). In (a) the corresponding M dynamics are given, in (b) the \log_{10} -transformed antibody concentration and in (c) the ASCs dynamics. The time axis is rescaled at the second dose day (*i.e.* day 57).

647 this would mean that after a few encounters with the same antigen, instead of
648 building up stronger immunity and memory like what is observed in real life
649 for many pathogens [62, 63, 64], the memory would have a lower level. With
650 these regards, we ran additional sensitivity analyses in which we decreased
651 the values of the parameters μ_S and μ_L for the booster dose of Ad26.ZEBOV

down to 10-fold lower values (Figure 7). We show that, by modifying these values the BMEMs (Figure 7 (a)) reach higher levels, while both the antibody levels (Figure 7 (b)) and the plasma cells levels (Figure 7 (c)) are similar for the different sets of parameters (μ_S, μ_L). Immunologically, the variation of parameters μ_S and μ_L for the booster dose can be justified by assuming a complete maturation (hence effectiveness upon antigen stimulation) of the BMEMs only at the time of the booster (and not at dose 1/dose 2) [57, 58].

If experimentally confirmed, these results would suggest the establishment of an effective immunological memory against Ebola virus, as a response to the two-dose vaccine regimen. Model predictions about the effects of a booster dose could be further evaluated when supplementary immunological data from a subgroup of ongoing phase II clinical studies which received booster dose of Ad26.ZEBOV will be available [65].

8. Discussion

Recurring Ebola outbreaks have been recorded in equatorial Africa since the discovery of Ebola virus in 1976, with the largest and more complex one occurred in West Africa between March 2014 and June 2016. We are now currently experiencing, in the DRC, the second largest outbreak ever recorded. A prophylactic vaccine against Ebola virus is urgently needed.

A new two-dose heterologous vaccine regimen against Ebola Virus based on Ad26.ZEBOV and MVA-BN-Filo developed by Janssen Vaccines & Prevention B.V. in collaboration with Bavarian Nordic is being evaluated in multiple clinical studies. The immune response following vaccination has been mainly assessed through specific binding antibody concentrations (Section 2). The level of circulating antibodies needed to ensure protection is currently unclear: persistence of antibody responses after the two-dose vaccination has been clinically observed up to one year after the first dose, yet at a lower level than shortly after vaccination. Since we don't currently know for how long the two-dose vaccine can convey protection, a booster vaccination can be considered in case of imminent risk of exposure to Ebola virus (pre-exposure booster vaccination).

687 We proposed an original mechanistic ODE-based model - (MSL) - which
688 takes into account the immunological memory (BMEMs) and short- and long-
689 lived ASCs dynamics (Section 3). This model, which is an extension of the
690 model developed by Andraud *et al.* [42], aimed at explaining the primary
691 response after receiving a first vaccine dose against Ebola virus, and the se-
692 condary response following a second heterologous vaccine dose. The final
693 goal of our model is to predict the speed and magnitude of the anamnes-
694 tic response triggered by a booster vaccination among individuals who have
695 been vaccinated with the two-dose regimen, and the long-term antibody per-
696 sistence afterward. Succeeding in this task will be extremely helpful to better
697 understand the immune response to a vaccine regimen.

698
699 We have performed structural identifiability analysis of (MSL) model
700 (Section 4), which pointed out that antibody concentrations data are not
701 sufficient to ensure (MSL) structural identifiability. Indeed, different param-
702 eter sets can reproduce the same antibody dynamic. In order to proceed
703 with proper parameter estimation, at least ASCs data should be integrated.
704 Alternatively, some parameters should be fixed to allow estimation of the
705 remaining ones.

706
707 In the absence of priors on structural non-identifiable parameters and of
708 additional biological data, we decided to proceed to model calibration (Sec-
709 tion 5). To perform (MSL) model calibration, we have repeatedly simulated
710 (MSL) using Matlab and compared the *Ab* output to median and interquar-
711 tile ranges of available ELISA data from all studies pooled together, stratified
712 by vaccination group. We have shown that (MSL) model is able to reproduce
713 qualitatively the observed antibody kinetics for a well-chosen set of param-
714 eters. This provides the rationale to test the ability of (MSL) in predicting
715 the speed and magnitude of the immune response to a booster vaccine dose.

716
717 Based on parameter values obtained through (MSL) model calibration,
718 we have performed local sensitivity analysis to assess to which extent each
719 parameter affects antibody dynamics over time (Section 6). Hence, a better
720 insight on practical identifiability of model parameters has been achieved in
721 a sensitivity-based manner.

722
723 Finally, the calibrated model has been used to evaluate *in silico* a booster
724 dose of Ad26.ZEBOV one year after the first dose (Section 7), showing a

strong humoral anamnestic response. If experimentally confirmed, this would increase confidence on the capacity of the proposed prophylactic regimen to induce a robust and durable immune response against Ebola virus.

In order to simplify the model structure, in (MSL) the M compartment describes the GC reaction and the contribution of the BMEM population to the immune response. Therefore, due to the intrinsic difference between the primary and the secondary responses, M cells do not play exactly the same role when a primary (GCs generated from activated naïve B cells) or a secondary (GCs seeded by BMEMs or newly activated naïve B cells; BMEMs differentiating into ASCs) response is simulated [22, 28]. For this reason, it is reasonable to adjust some parameters (*e.g.* $\rho, \delta_S, \mu_S, \mu_L$) from one immunization to the following one, eventually also based on the time between the two doses. In particular, an improved antibody response has been experimentally observed when the delay between the first and second doses is higher (*e.g.* 56 days schedule compared to 28 days). Therefore, according to sensitivity analysis performed in Section 6, we suggest to investigate through modeling the possibility of an increase of parameters ρ and μ_L when increasing the time lapse between the two doses, the opposite for parameters μ_S and δ_S . Note that the effect of timing of the second dose on the half-life of short-lived ASCs has been already observed by Pasin and coauthors [47].

Moreover, due to (MSL) definition, if we do not change any parameter among $\{\rho, \mu_L, \mu_S\}$ from the first to following doses, BMEMs level remains almost unchanged (Section 3.3), while we expect an increase in the concentration of BMEMs after the booster dose.

After vaccination, the existence of a plateau reached by functional persisting BMEMs has been reported in the literature [49]. In (MSL) this plateau is quickly reached, due to the fact that we do not consider here any intermediate maturation step from naïve to activated to functional differentiated cells: when the antigen is introduced in the system, the M compartment is almost instantaneously filled. The main consequence is that the contribution of this compartment to enhance the secondary response will be substantially unchanged regardless the time delay between two subsequent vaccine immunizations, in the situation in which no parameter modification is permitted.

Despite the simplifications in model structure, several identifiability is-

763 issues have been raised in Sections 4 and 6. Consequently, another limitation
 764 of this study is that model parameters could not be accurately and univocally
 765 determined.

766
 767 The (MSL) model provides a good starting point to evaluate the humoral
 768 immune response elicited by the proposed vaccination regimens. Several fu-
 769 ture research directions can be suggested by this work. For instance, (MSL)
 770 model can be further refined using future data that will be available from
 771 ongoing phase II and III clinical studies, in particular regarding B cell pop-
 772 ulations and immune response after a booster vaccination. Other questions
 773 should be addressed *in silico*. In particular, (MSL) model could be gener-
 774 alized by relaxing the assumption of replication deficient vaccine vectors to
 775 allow the study of the immune response elicited by live attenuated vaccine
 776 virus. Indeed, it would be interesting to test (MSL) with other vaccination
 777 studies, to determine whether some parameters are independent from the type
 778 of vaccine vector used.

779 9. Conclusion

780 In this work we set a mechanistic model - (MSL)- of the humoral immune
 781 response to one or more vaccine immunizations, based on an ODE system
 782 of 5 equations. It describes the interaction between the antigen delivered by
 783 replication deficient vaccine vectors, BMEMs, ASCs (distinguishing two pop-
 784 ulations differing by their respective half-lives) and produced antigen-specific
 785 antibodies. We have analyzed model structure identifying which kind of bi-
 786 ological data should be collected or alternatively which parameters should
 787 be fixed to perform proper parameter estimations. By confronting (MSL)
 788 with ELISA data from two-dose heterologous vaccination regimens against
 789 Ebola virus, we show that the model is able to reproduce realistic antibody
 790 concentration dynamics after the two-dose heterologous vaccination. This
 791 provides the rationale to test the ability of (MSL) in predicting the speed
 792 and magnitude of the immune response to a booster vaccine dose, as we show
 793 in this paper, and investigate long-term antibody persistence. Our findings
 794 raise interesting further questions. Some of them require further biological
 795 data, in particular regarding B cell populations assessment. Also, one could
 796 be interested in understanding if some model parameters are intrinsic prop-
 797 erties of the immune response, hence could help describing the response to
 798 natural infection. Other questions should be addressed *in silico* to explore

799 the interaction of additional immune components and their contribution to
800 the establishment, maintenance and reactivation of the immune response to
801 a repeatedly presented antigen.

802 10. Acknowledgments

803 We thank the members of the EBOVAC1 consortium, in particular the
804 principal investigators of the EBOVAC1 trials, Matthew Snape, Omu Anzala,
805 George Praygod, Zacchaeus Anywaine. We also thank Andrew Pollard and
806 Elizabeth Clutterbuck for scientific discussions.

807 In addition, we thank the members of the EBOVAC3 consortium and
808 in particular Rosalind Eggo, Niel Hens, Carl Pearson and Bart Spiessens,
809 involved in the modeling effort supporting the development of the two-dose
810 heterologous regimen developed by Janssen Vaccines & Prevention B.V., and
811 discussed in this paper.

812 This work has received funding from the Innovative Medicines Initiative
813 2 Joint Undertaking under Grant Agreement EBOVAC1 (No. 115854). This
814 Joint Undertaking receives support from the European Union's Horizon 2020
815 research and innovation programme and EFPIA. The funder of the study had
816 no role in the study design, data collection, data analysis, data interpreta-
817 tion, or writing the report. The corresponding author had full access to all
818 the data in the study and had final responsibility for the decision to sub-
819 mit for publication. This work was also supported by the Investissements
820 d'Avenir program managed by the ANR under reference ANR-10-LABX-77.
821 The funder had no role in the study design, data collection, data analysis,
822 data interpretation, or writing the report.

823 Competing interests: TVE, VB and LS are employees of Janssen Phar-
824 maceuticals and may be Johnson & Johnson stockholders.

825 References

- 826 [1] W. E. R. Team, After ebola in west africa - unpredictable risks, pre-
827 ventable epidemics, *New England Journal of Medicine* 375 (6) (2016)
828 587–596.
- 829 [2] World Health Organisation, Ebola virus disease, Fact Sheet,
830 [https://www.who.int/news-room/fact-sheets/detail/ebola-](https://www.who.int/news-room/fact-sheets/detail/ebola-virus-disease)
831 [virus-disease](https://www.who.int/news-room/fact-sheets/detail/ebola-virus-disease), Last accessed on 2019-05-04 (2018).

- 832 [3] W. H. Organization, et al., Situation report: Ebola virus disease, 10
833 june 2016, World Health Organization, Geneva.
- 834 [4] W. H. Organization, et al., Ebola situation reports: Democratic republic
835 of the congo (2018).
- 836 [5] World Health Organisation, Ebola virus disease, Democratic Republic of
837 the Congo, External Situation Report N°82/2019, [https://www.who.
838 int/publications-detail/ebola-virus-disease-democratic-
839 republic-of-congo-external-situation-report-82-2019](https://www.who.int/publications-detail/ebola-virus-disease-democratic-republic-of-congo-external-situation-report-82-2019), Last
840 accessed on 2020-03-05 (2019).
- 841 [6] World Health Organisation, Statement on the meeting of the In-
842 ternational Health Regulations (2005) Emergency Committee for
843 Ebola virusdisease in the Democratic Republic of the Congo on
844 17 July 2019, [https://www.who.int/ihr/procedures/statement-
845 emergency-committee-ebola-drc-july-2019.pdf](https://www.who.int/ihr/procedures/statement-emergency-committee-ebola-drc-july-2019.pdf), Last accessed on
846 2019-07-23 (2019).
- 847 [7] T. Goldstein, S. J. Anthony, A. Gbakima, B. H. Bird, J. Bangura,
848 A. Tremeau-Bravard, M. N. Belaganahalli, H. L. Wells, J. K. Dhanota,
849 E. Liang, et al., The discovery of bombali virus adds further support for
850 bats as hosts of ebolaviruses, *Nature microbiology* 3 (10) (2018) 1084.
- 851 [8] L. Gross, E. Lhomme, C. Pasin, L. Richert, R. Thiebaut, Ebola vac-
852 cine development: Systematic review of pre-clinical and clinical studies,
853 and meta-analysis of determinants of antibody response variability af-
854 ter vaccination, *International Journal of Infectious Diseases* 74 (2018)
855 83–96.
- 856 [9] N. Venkatraman, D. Silman, P. M. Folegatti, A. V. Hill, Vaccines against
857 ebola virus, *Vaccine* 36 (36) (2018) 5454–5459.
- 858 [10] Eurosurveillance editorial team, First innovative medicines initiative
859 ebola projects launched, *Eurosurveillance* 20 (3) (2015) 21014.
- 860 [11] I. D. Milligan, M. M. Gibani, R. Sewell, E. A. Clutterbuck, D. Campbell,
861 E. Pledsted, E. Nuthall, M. Voysey, L. Silva-Reyes, M. J. McElrath, et al.,
862 Safety and immunogenicity of novel adenovirus type 26–and modified
863 vaccinia ankara–vectored ebola vaccines: a randomized clinical trial,
864 *Jama* 315 (15) (2016) 1610–1623.

- 865 [12] R. L. Winslow, I. D. Milligan, M. Voysey, K. Luhn, G. Shukarev,
866 M. Douoguih, M. D. Snape, Immune responses to novel adenovirus type
867 26 and modified vaccinia virus ankara–vectored ebola vaccines at 1 year,
868 *Jama* 317 (10) (2017) 1075–1077.
- 869 [13] G. Mutua, O. Anzala, K. Luhn, C. Robinson, V. Bockstal, D. Anu-
870 mendem, M. Douoguih, Safety and immunogenicity of a 2-dose heterol-
871 ogous vaccine regimen with Ad26. ZEBOV and MVA-BN-Filo Ebola
872 vaccines: 12-month data from a phase 1 randomized clinical trial in
873 Nairobi, Kenya, *The Journal of infectious diseases* 220 (1) (2019) 57–67.
- 874 [14] Z. Anywaine, H. Whitworth, P. Kaleebu, G. Praygod, G. Shukarev,
875 D. Manno, S. Kapiga, H. Grosskurth, S. Kalluvya, V. Bockstal, et al.,
876 Safety and immunogenicity of a 2-dose heterologous vaccination regimen
877 with Ad26. ZEBOV and MVA-BN-Filo Ebola vaccines: 12-month data
878 from a phase 1 randomized clinical trial in Uganda and Tanzania, *The*
879 *Journal of Infectious Diseases* 220 (1) (2019) 46–56.
- 880 [15] N. J. Sullivan, J. E. Martin, B. S. Graham, G. J. Nabel, Correlates
881 of protective immunity for ebola vaccines: implications for regulatory
882 approval by the animal rule, *Nature Reviews Microbiology* 7 (5) (2009)
883 393.
- 884 [16] G. Wong, J. S. Richardson, S. Pillet, A. Patel, X. Qiu, J. Alimonti,
885 J. Hogan, Y. Zhang, A. Takada, H. Feldmann, et al., Immune param-
886 eters correlate with protection against ebola virus infection in rodents
887 and nonhuman primates, *Science translational medicine* 4 (158) (2012)
888 158ra146–158ra146.
- 889 [17] J. M. Dye, A. S. Herbert, A. I. Kuehne, J. F. Barth, M. A. Muham-
890 mad, S. E. Zak, R. A. Ortiz, L. I. Prugar, W. D. Pratt, Postexposure
891 antibody prophylaxis protects nonhuman primates from filovirus dis-
892 ease, *Proceedings of the National Academy of Sciences* 109 (13) (2012)
893 5034–5039.
- 894 [18] B. Callendret, J. Vellinga, K. Wunderlich, A. Rodriguez, R. Steigerwald,
895 U. Dirmeier, C. Cheminay, A. Volkmann, T. Brasel, R. Carrion, et al., A
896 prophylactic multivalent vaccine against different filovirus species is im-
897 munogenic and provides protection from lethal infections with ebolavirus

- 898 and marburgvirus species in non-human primates, PloS one 13 (2) (2018)
899 e0192312.
- 900 [19] B. Pulendran, R. Ahmed, Translating innate immunity into immunolog-
901 ical memory: implications for vaccine development, Cell 124 (4) (2006)
902 849–863.
- 903 [20] L. Hviid, L. Barfod, F. J. Fowkes, Trying to remember: immunological
904 B cell memory to malaria, Trends in parasitology 31 (3) (2015) 89–94.
- 905 [21] D. L. Farber, M. G. Netea, A. Radbruch, K. Rajewsky, R. M. Zinker-
906 nagel, Immunological memory: lessons from the past and a look to the
907 future, Nature Reviews Immunology 16 (2) (2016) 124.
- 908 [22] T. Inoue, I. Moran, R. Shinnakasu, T. G. Phan, T. Kurosaki, Generation
909 of memory B cells and their reactivation, Immunological reviews 283 (1)
910 (2018) 138–149.
- 911 [23] G. D. Victora, M. C. Nussenzweig, Germinal centers, Annual review of
912 immunology 30 (2012) 429–457.
- 913 [24] N. S. De Silva, U. Klein, Dynamics of B cells in germinal centres, Nature
914 reviews immunology 15 (3) (2015) 137.
- 915 [25] M. J. Carter, R. M. Mitchell, P. M. Meyer Sauter, D. F. Kelly, J. Trück,
916 The antibody-secreting cell response to infection: Kinetics and clinical
917 applications, Frontiers in immunology 8 (2017) 630.
- 918 [26] J. L. Halliley, S. Kyu, J. J. Kobie, E. E. Walsh, A. R. Falsey, T. D.
919 Randall, J. Treanor, C. Feng, I. Sanz, F. E.-H. Lee, Peak frequencies
920 of circulating human influenza-specific antibody secreting cells corre-
921 late with serum antibody response after immunization, Vaccine 28 (20)
922 (2010) 3582–3587.
- 923 [27] S. Leach, A. Lundgren, A.-M. Svennerholm, Different kinetics of circu-
924 lating antibody-secreting cell responses after primary and booster oral
925 immunizations: a tool for assessing immunological memory, Vaccine
926 31 (30) (2013) 3035–3038.
- 927 [28] A. A. Ademokun, D. Dunn-Walters, Immune responses: primary and
928 secondary, Encyclopedia of Life Sciences.

- 929 [29] S. G. Tangye, D. T. Avery, E. K. Deenick, P. D. Hodgkin, Intrinsic
930 differences in the proliferation of naive and memory human B cells as a
931 mechanism for enhanced secondary immune responses, *The Journal of*
932 *Immunology* 170 (2) (2003) 686–694.
- 933 [30] M. J. Shlomchik, Do memory B cells form secondary germinal centers?
934 yes and no, *Cold Spring Harbor perspectives in biology* 10 (1) (2018)
935 a029405.
- 936 [31] J. L. Halliley, C. M. Tipton, J. Liesveld, A. F. Rosenberg, J. Darce, I. V.
937 Gregoret, L. Popova, D. Kaminiski, C. F. Fucile, I. Albizua, et al.,
938 Long-lived plasma cells are contained within the cd19- cd38hicd138+
939 subset in human bone marrow, *Immunity* 43 (1) (2015) 132–145.
- 940 [32] E. Hammarlund, A. Thomas, I. J. Amanna, L. A. Holden, O. D. Slayden,
941 B. Park, L. Gao, M. K. Slifka, Plasma cell survival in the absence of B
942 cell memory, *Nature communications* 8 (1) (2017) 1781.
- 943 [33] F. Nommensen, S. Go, D. MacLaren, Half-life of hbs antibody after
944 hepatitis b vaccination: an aid to timing of booster vaccination, *The*
945 *Lancet* 334 (8667) (1989) 847–849.
- 946 [34] K. Van Herck, P. Van Damme, Inactivated hepatitis a vaccine-induced
947 antibodies: follow-up and estimates of long-term persistence, *Journal of*
948 *medical virology* 63 (1) (2001) 1–7.
- 949 [35] I. Van Twillert, A. A. B. Marinović, B. Kuipers, E. A. Sanders, C. A. van
950 Els, et al., Impact of age and vaccination history on long-term serological
951 responses after symptomatic b. pertussis infection, a high dimensional
952 data analysis, *Scientific Reports* 7 (2017) 40328.
- 953 [36] M. B. van Ravenhorst, A. B. Marinovic, F. R. van der Klis, D. M. van
954 Rooijen, M. van Maurik, S. P. Stoof, E. A. Sanders, G. A. Berbers, Long-
955 term persistence of protective antibodies in dutch adolescents following a
956 meningococcal serogroup c tetanus booster vaccination, *Vaccine* 34 (50)
957 (2016) 6309–6315.
- 958 [37] P. Teunis, O. Van Der Heijden, H. De Melker, J. Schellekens, F. Ver-
959 steegh, M. Kretzschmar, Kinetics of the igg antibody response to per-
960 tussis toxin after infection with b. pertussis, *Epidemiology & Infection*
961 129 (3) (2002) 479–489.

- [38] D. Le, J. D. Miller, V. V. Ganusov, Mathematical modeling provides kinetic details of the human immune response to vaccination, *Frontiers in cellular and infection microbiology* 4 (2015) 177.
- [39] R. J. De Boer, M. Oprea, R. Antia, R. Ahmed, A. S. Perelson, K. Muralikrishna, Recruitment Times, Proliferation, and Apoptosis Rates during the CD8⁺ T-cell Response to Lymphocytic Choriomeningitis Virus, *J. Virol.* doi:10.1128/JVI.75.22.10663.
- [40] R. Antia, C. T. Bergstrom, S. S. Pilyugin, S. M. Kaech, R. Ahmed, Models of CD8+ Responses: 1. What is the Antigen-independent Proliferation Program, *J. Theor. Biol.* 221 (4) (2003) 585–598. doi:10.1006/jtbi.2003.3208.
URL <http://linkinghub.elsevier.com/retrieve/pii/S0022519303932085>
- [41] C. Fraser, J. E. Tomassini, L. Xi, G. Golm, M. Watson, A. R. Giuliano, E. Barr, K. A. Ault, Modeling the long-term antibody response of a human papillomavirus (hpv) virus-like particle (vlp) type 16 prophylactic vaccine, *Vaccine* 25 (21) (2007) 4324–4333.
- [42] M. Andraud, O. Lejeune, J. Z. Musoro, B. Ogunjimi, P. Beutels, N. Hens, Living on three time scales: the dynamics of plasma cell and antibody populations illustrated for hepatitis a virus, *PLoS Comput Biol* 8 (3) (2012) e1002418.
- [43] M. T. White, J. T. Griffin, O. Akpogheneta, D. J. Conway, K. A. Koram, E. M. Riley, A. C. Ghani, Dynamics of the antibody response to plasmodium falciparum infection in african children, *The Journal of infectious diseases* 210 (7) (2014) 1115–1122.
- [44] J. N. Wilson, D. J. Nokes, Do we need 3 doses of hepatitis b vaccine?, *Vaccine* 17 (20) (1999) 2667–2673.
- [45] J. N. Wilson, D. J. Nokes, G. F. Medley, D. Shouval, Mathematical model of the antibody response to hepatitis b vaccines: implications for reduced schedules, *Vaccine* 25 (18) (2007) 3705–3712.
- [46] C. L. Davis, R. Wahid, F. R. Toapanta, J. K. Simon, M. B. Sztein, A clinically parameterized mathematical model of shigella immunity to inform vaccine design, *PloS one* 13 (1) (2018) e0189571.

- 995 [47] C. Pasin, I. Balelli, T. Van Effelterre, V. Bockstal, L. Solforosi,
996 M. Prague, M. Douoguih, R. Thiébaut, [Dynamics of the humoral](#)
997 [immune response to a prime-boost ebola vaccine: quantification and](#)
998 [sources of variation](#), Journal of Virology [doi:10.1128/JVI.00579-19](#).
999 URL [https://jvi.asm.org/content/early/2019/06/20/JVI.](https://jvi.asm.org/content/early/2019/06/20/JVI.00579-19)
1000 [00579-19](#)
- 1001 [48] D. D. Jones, J. R. Wilmore, D. Allman, Cellular dynamics of memory
1002 B cell populations: IgM+ and IgG+ memory B cells persist indefinitely
1003 as quiescent cells, The Journal of Immunology (2015) 1501365.
- 1004 [49] S. Crotty, P. Felgner, H. Davies, J. Glidewell, L. Villarreal, R. Ahmed,
1005 Cutting edge: long-term B cell memory in humans after smallpox vac-
1006 cination, The Journal of Immunology 171 (10) (2003) 4969–4973.
- 1007 [50] P. Hartman, C. Olech, On global asymptotic stability of solutions of dif-
1008 ferential equations, Transactions of the American Mathematical Society
1009 104 (1) (1962) 154–178.
- 1010 [51] H. Miao, X. Xia, A. S. Perelson, H. Wu, On identifiability of nonlinear
1011 ode models and applications in viral dynamics, SIAM review 53 (1)
1012 (2011) 3–39.
- 1013 [52] H. B. Shah, K. A. Koelsch, B-cell elispot: for the identification of
1014 antigen-specific antibody-secreting cells, in: Western Blotting, Springer,
1015 2015, pp. 419–426.
- 1016 [53] M. Lavielle, L. Aarons, What do we mean by identifiability in mixed
1017 effects models?, Journal of pharmacokinetics and pharmacodynamics
1018 43 (1) (2016) 111–122.
- 1019 [54] J. Guedj, R. Thiébaut, D. Commenges, Maximum likelihood estimation
1020 in dynamical models of hiv, Biometrics 63 (4) (2007) 1198–1206.
- 1021 [55] M. Prague, D. Commenges, J. Guedj, J. Drylewicz, R. Thiébaut, Nim-
1022 rod: A program for inference via a normal approximation of the posterior
1023 in models with random effects based on ordinary differential equations,
1024 Computer methods and programs in biomedicine 111 (2) (2013) 447–
1025 458.

- 1026 [56] F. Sallusto, A. Lanzavecchia, K. Araki, R. Ahmed, From vaccines to
1027 memory and back, *Immunity* 33 (4) (2010) 451–463.
- 1028 [57] W. Jilg, M. Schmidt, F. Deinhardt, Vaccination against hepatitis b:
1029 comparison of three different vaccination schedules, *Journal of Infectious*
1030 *Diseases* 160 (5) (1989) 766–769.
- 1031 [58] R. B. Belshe, S. E. Frey, I. Graham, M. J. Mulligan, S. Edupuganti,
1032 L. A. Jackson, A. Wald, G. Poland, R. Jacobson, H. L. Keyserling,
1033 et al., Safety and immunogenicity of influenza a h5 subunit vaccines:
1034 effect of vaccine schedule and antigenic variant, *Journal of Infectious*
1035 *Diseases* 203 (5) (2011) 666–673.
- 1036 [59] R. L. Sheets, J. Stein, R. T. Bailer, R. A. Koup, C. Andrews, M. Nason,
1037 B. He, E. Koo, H. Trotter, C. Duffy, et al., Biodistribution and toxico-
1038 logical safety of adenovirus type 5 and type 35 vectored vaccines against
1039 human immunodeficiency virus-1 (hiv-1), ebola, or marburg are similar
1040 despite differing adenovirus serotype vector, manufacturer’s construct,
1041 or gene inserts, *Journal of immunotoxicology* 5 (3) (2008) 315–335.
- 1042 [60] T. Hanke, A. J. McMichael, M. J. Dennis, S. A. Sharpe, L. A. Powell,
1043 L. McLoughlin, S. J. Crome, Biodistribution and persistence of an mva-
1044 vectored candidate hiv vaccine in siv-infected rhesus macaques and scid
1045 mice, *Vaccine* 23 (12) (2005) 1507–1514.
- 1046 [61] Z. Zi, Sensitivity analysis approaches applied to systems biology models,
1047 *IET systems biology* 5 (6) (2011) 336–346.
- 1048 [62] G.-M. Li, C. Chiu, J. Wrammert, M. McCausland, S. F. Andrews, N.-
1049 Y. Zheng, J.-H. Lee, M. Huang, X. Qu, S. Edupuganti, et al., Pan-
1050 demic h1n1 influenza vaccine induces a recall response in humans that
1051 favors broadly cross-reactive memory b cells, *Proceedings of the National*
1052 *Academy of Sciences* 109 (23) (2012) 9047–9052.
- 1053 [63] J. Lessler, S. Riley, J. M. Read, S. Wang, H. Zhu, G. J. Smith, Y. Guan,
1054 C. Q. Jiang, D. A. Cummings, Evidence for antigenic seniority in in-
1055 fluenza a (h3n2) antibody responses in southern china, *PLoS pathogens*
1056 8 (7).
- 1057 [64] C. Green, C. Sande, C. De Lara, A. Thompson, L. Silva-Reyes,
1058 F. Napolitano, A. Pierantoni, S. Capone, A. Vitelli, P. Klennerman, et al.,

- Humoral and cellular immunity to rsv in infants, children and adults, Vaccine 36 (41) (2018) 6183–6190.
- [65] Ebovac2, 7th Ebovac2 e-newsletter, http://www.ebovac2.com/images/EBOVAC2__newsletter7_19112018.pdf, Last accessed on 2020-01-31 (2018).
- [66] J. Karlsson, M. Anguelova, M. Jirstrand, An efficient method for structural identifiability analysis of large dynamic systems, IFAC Proceedings Volumes 45 (16) (2012) 941–946.
- [67] A. Sedoglavic, A probabilistic algorithm to test local algebraic observability in polynomial time, in: Proceedings of the 2001 international symposium on Symbolic and algebraic computation, ACM, 2001, pp. 309–317.
- [68] H. Pohjanpalo, System identifiability based on the power series expansion of the solution, Mathematical biosciences 41 (1-2) (1978) 21–33.
- [69] Victor M. Garcia-Molla, Sensitivity analysis for odes and daes, MATLAB Central File Exchange, <https://fr.mathworks.com/matlabcentral/fileexchange/1480-sensitivity-analysis-for-odes-and-daes>, Retrieved on 2017-09-07 (2017).
- [70] H. G. Bock, Numerical treatment of inverse problems in chemical reaction kinetics, in: Modelling of chemical reaction systems, Springer, 1981, pp. 102–125.

Appendix

Appendix A. The IdentifiabilityAnalysis package

In order to assess the *a priori* local structural identifiability of (MSL) we use the Exact Arithmetic Rank (EAR) approach implemented in Mathematica through the `IdentifiabilityAnalysis` package [66]. It is the Mathematica implementation of a probabilistic semi-numerical algorithm described in [67] based on rank computation of a numerically instantiated Jacobian matrix. This is called the rank test for structural identifiability [68].

1088 **Appendix B. Matlab function `sens_ind` for numerical evaluation of**
1089 **partial derivatives**

1090 To evaluate the first-order partial derivatives of model outputs with re-
1091 spect to its parameters around a local point in the parameter space, we use
1092 Matlab function `sens_ind` [69]. It is based on Matlab function `ode15` and
1093 is able to compute the derivatives of an ODE system with respect to its
1094 parameters, by using the *Internal Numerical Differentiation* approach [70].





Figure S1: Antibody concentrations dynamics per site and vaccination groups in \log_{10} scale [47]. Medians and interquartile ranges are given.

Table S1: Summary of data in all studies.


	UK	Kenya	Uganda/ Tanzania	Total
Number of participants, No.	59	59	59	177
Group MVA/Ad26 D29	15	14 (1 un- completed)	15	44
Group MVA/Ad26 D57	15	15	14 (1 un- completed)	44
Group Ad26/MVA D29	15	15	15	45
Group Ad26/MVA D57	14 (1 lost of follow-up)	15	15	44
Antibody concentrations (log₁₀ ELISA Units/mL), Mean (sd)	Detection level: 1.56	Detection level: 1.42	Detection level: 1.56	
Second dose injection day (first dose: Ad26.ZEBOV)	2.83 (0.5)	2.55 (0.44)	2.56 (0.43)	2.64 (0.47)
Second dose injection day (first dose: MVA-BN- Filo)	1.46 (0.36)	1.69 (0.48)	1.45 (0.46)	1.54 (0.44)
360 days post first dose (Ad26/MVA regimen)	3.24 (0.41)	2.63 (0.44)	2.74 (0.45)	2.85 (0.5)
360 days post first dose (MVA/Ad26 regimen)	3.51 (0.35)	2.77 (0.4)	2.84 (0.32)	3.03 (0.48)

Table S2: Details of the identifiability analysis results performed with `IdentifiabilityAnalysis` package (Section 4) for the (MSL) model. One can obtain the corresponding results for the reduced model (6) by supposing a_0 known. **DoF** = Degree of Freedom.


Input	Available outputs	Identifiability	DoF	Non-identifiable parameters
$\text{sys} = \{a'[t] = -da * a[t],$ $m'[t] = r * a[t] - (ms + ml) * a[t] * m[t] - dm * m[t],$ $s'[t] = ms * a[t] * m[t] - ds * s[t],$ $l'[t] = ml * a[t] * m[t] - dl * l[t],$ $Ab'[t] = ts * s[t] + tl * l[t] - dAb * Ab[t],$ $a[0] = a_0, m[0] = m_0, s[0] = s_0,$ $l[0] = l_0, Ab[0] = Ab_0\};$ $\text{states} = \{a, m, s, l, Ab\}$ $\text{params} = \{da, r, ms, ml, dm, ds, dl, ts, tl, db, a_0, m_0,$ $s_0, l_0, Ab_0\};$	$Ab_0, Ab[t]$	False	3	$a_0, m_0, s_0, l_0, r,$ ms, ml, tl, ts
	$Ab_0, Ab[t],$ ml, ms, r	True		
	$Ab_0, Ab[t],$ ml, ms, tl	True		
	$Ab_0, Ab[t],$ ml, ms, ts	True		
	$Ab_0, Ab[t],$ ml, r, ts	True		
	$Ab_0, Ab[t],$ ml, r, tl	True		
	$Ab_0, Ab[t],$ ml, tl, ts	True		
	$Ab_0, Ab[t],$ ms, r, ts	True		
	$Ab_0, Ab[t],$ ms, r, tl	True		
	$Ab_0, Ab[t],$ ms, tl, ts	True		
	$Ab_0, Ab[t],$ $s[t] + l[t]$	False	1	a_0, ml, ms, r
	$Ab_0, Ab[t],$ $s[t] + l[t], a_0$	True		
	$Ab_0, Ab[t],$ $m[t]$	False	2	$a_0, l_0, ml, ms, r, s_0,$ tl, ts




(a) $Ab(t)$, Ad26/MVA D29



(b) $Ab(t)$, Ad26/MVA D57




(c) B cells, Ad26/MVA D29




(d) B cells, Ad26/MVA D57


Figure S2: Results of the calibration of (6) (Section 5) for groups Ad26/MVA D29 (left column) and Ad26/MVA D57 (right column). In (a-b) green horizontal lines denote detection levels used by the BBRC laboratory (solid line) and by the Q2 Solutions laboratory (dashed line) respectively. Antibodies are \log_{10} -transformed.




(a) $Ab(t)$, MVA/Ad26 D29



(b) $Ab(t)$, MVA/Ad26 D57



(c) B cells, MVA/Ad26 D29



(d) B cells, MVA/Ad26 D57

Figure S3: Results of the calibration of (6) (Section 5) for groups MVA/Ad26 D29 (left column) and MVA/Ad26 D57 (right column). In (a-b) green horizontal lines denote detection levels used by the BBRC laboratory (solid line) and by the Q2 Solutions laboratory (dashed line) respectively. Antibodies are \log_{10} -transformed.

Table S3: Antibody concentrations (in linear scale) obtained by model calibration for all vaccination groups, at some time points: the day of the second immunization (2D day), 21 days after the second dose (P2D) and 360 days after the first dose. We compare simulated values obtained with (6) with the parameter set detailed in Table 4 to data described in Section 2.

Group		2D day	21 days P2D	Day 360
Ad26/MVA D29	simulated value	613	4324	565
	data, median (iqr)	492 (625)	4349 (5768)	693 (1268)
Ad26/MVA D57	simulated value	489	8147	670
	data, median (iqr)	550 (797)	12468 (15151)	671 (1360)
MVA/Ad26 D29	simulated value	28	8954	981
	data, median (iqr)	18 (55)	8101 (6736)	1009 (2340)
MVA/Ad26 D57	simulated value	27	13354	994
	data, median (iqr)	18 (53)	14276 (14077)	740 (1556)

Table S4: Antibody concentrations (in linear scale) obtained by simulation of (6) with a booster Ad26.ZEBOV immunization realized 1 year after the first dose (day 360). We compare vaccination groups Ad26/MVA D29 and Ad26/MVA D57.

Immunization schedule	Day 360	Day 367	Day 381	Day 720
Ad26/MVA D29 + Ad26 D360	576	7054	16943	1647
Ad26/MVA D57 + Ad26 D360	683	7635	17584	1767